| Carbamazepine, HLA-B*1502 and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations PB Ferrell, HL McLeod Pharmacogenomics 9 (10), 1543-1546, 2008 | 546 | 2008 |
| T cells specific for α-myosin drive immunotherapy-related myocarditis ML Axelrod, WC Meijers, EM Screever, J Qin, MG Carroll, X Sun, ... Nature 611 (7937), 818-826, 2022 | 293 | 2022 |
| Hematologic complications of immune checkpoint inhibitors EJ Davis, JE Salem, A Young, JR Green, PB Ferrell, KK Ancell, ... The Oncologist 24 (5), 584-588, 2019 | 173 | 2019 |
| Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement DB Johnson, MJ Nixon, Y Wang, DY Wang, E Castellanos, MV Estrada, ... JCI insight 3 (24), e120360, 2018 | 171 | 2018 |
| Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data KE Diggins, PB Ferrell Jr, JM Irish Methods 82, 55-63, 2015 | 159 | 2015 |
| Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial JM Watts, MR Baer, J Yang, T Prebet, S Lee, GJ Schiller, SN Dinner, ... The Lancet Haematology 10 (1), e46-e58, 2023 | 125 | 2023 |
| Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow M Roussel, PB Ferrell Jr, AR Greenplate, F Lhomme, S Le Gallou, ... Journal of leukocyte biology 102 (2), 437-447, 2017 | 112 | 2017 |
| The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia M Byrne, N Danielson, S Sengsayadeth, A Rasche, K Culos, K Gatwood, ... American Journal of Hematology 95 (9), 1006-1014, 2020 | 66 | 2020 |
| Alterations of T-cell-mediated immunity in acute myeloid leukemia Z Li, M Philip, PB Ferrell Oncogene 39 (18), 3611-3619, 2020 | 66 | 2020 |
| Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics DC Earl, PB Ferrell Jr, N Leelatian, JT Froese, BJ Reisman, JM Irish, ... Nature Communications 9 (1), 39, 2018 | 55 | 2018 |
| High-dimensional analysis of acute myeloid leukemia reveals phenotypic changes in persistent cells during induction therapy PB Ferrell Jr, KE Diggins, HG Polikowsky, SR Mohan, AC Seegmiller, ... PloS one 11 (4), e0153207, 2016 | 53 | 2016 |
| Systems immune monitoring in cancer therapy AR Greenplate, DB Johnson, PB Ferrell Jr, JM Irish European journal of cancer 61, 77-84, 2016 | 52 | 2016 |
| Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment K von Beck, T von Beck, PB Ferrell Jr, AG Bick, A Kishtagari Blood Cancer Journal 13 (1), 5, 2023 | 51 | 2023 |
| Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia T Guess, CR Potts, P Bhat, JA Cartailler, A Brooks, C Holt, A Yenamandra, ... Blood Cancer Discovery 3 (4), 316-329, 2022 | 49 | 2022 |
| Metabolic alterations mediated by STAT3 promotes drug persistence in CML SB Patel, T Nemkov, D Stefanoni, GA Benavides, MA Bassal, BL Crown, ... Leukemia 35 (12), 3371-3382, 2021 | 49 | 2021 |
| Bone marrow Tregs mediate stromal cell function and support hematopoiesis via IL-10 V Camacho, VR Matkins, SB Patel, JM Lever, Z Yang, L Ying, AE Landuyt, ... JCI insight 5 (22), e135681, 2020 | 47 | 2020 |
| Computational immune monitoring reveals abnormal double-negative T cells present across human tumor types AR Greenplate, DD McClanahan, BK Oberholtzer, DB Doxie, CE Roe, ... Cancer Immunology Research 7 (1), 86-99, 2019 | 43 | 2019 |
| Disordered immune regulation and its therapeutic targeting in myelodysplastic syndromes KS Ivy, P Brent Ferrell Jr Current hematologic malignancy reports 13 (4), 244-255, 2018 | 43 | 2018 |
| A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). JM Watts, MR Baer, S Lee, J Yang, SN Dinner, T Prebet, GJ Schiller, ... Journal of Clinical Oncology 36 (15_suppl), 7009-7009, 2018 | 40 | 2018 |
| Olutasidenib (FT-2102), an IDH1m inhibitor as a single agent or in combination with azacitidine, induces deep clinical responses with mutation clearance in patients with acute … JM Watts, MR Baer, J Yang, T Prebet, S Lee, GJ Schiller, S Dinner, ... Blood 134, 231, 2019 | 37 | 2019 |
Michael SavonaProfessor of Medicine and Cancer Biology, Vanderbilt UniversityVerified email at vanderbilt.edu
